18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes

Table 1 Subject demographics

	nfvPPA	CBS	MAPT	bvFTD	C9ORF72, GRN	svPPA	All patients	NC
N	11	10	6	10	6	2	45	53
Age	64 (56, 75)	68 (54, 77)	52 (37, 68)	68 (34, 78)	61 (48, 71)	59, 71	63 (34, 78)	76 (20, 93)
Education	15 (12, 24)	16 (13, 20)^┼	16 (14, 18)	16 (12, 20)	18 (12, 20)	12, 18	16 (12, 24)	17 (13, 20) ^┼
Handedness (R/L)	8/3	9/1	6/0	9/1	6/0	2/0	40/5	49/3^┼
Sex (F/M)	8/3	5/5	2/4	1/9	4/2	1/1	21/24	23/30
MMSE	26 (17, 30)	27 (9, 30) ^┼	18 (4, 30)	22 (18, 29)	26 (21, 26)	25, 28	24 (4, 30)	29 (25, 30)*
CDR-SB	0.8 (0, 3)**	2 (1, 7) ^┼	7 (1, 10)	7 (1.5, 12)	6 (0.5, 8)	3.5, 3.5	3.9 (0, 12)	NA
Aβ (+/−)	0/11	4/6	1/5	3/6^┼	1/4^┼	0/2	9/34	0/44^‡
ApoE E4 (+/−)	2/9	4/5^┼	2/3^┼	0/10	2/4	0/2	10/33	7/43^┼

nfvPPA nonfluent variant primary progressive aphasia, CBS corticobasal syndrome, MAPT microtubule associated protein tau, bvFTD behavioral variant frontotemporal dementia, C9ORF72 chromosome 9 open reading frame 72 gene, GRN progranulin, svPPA semantic variant primary progressive aphasia, NC normal control, MMSE Mini-Mental State Examination, CDR-SB clinical dementia rating score sum of boxes, NA not applicable, Aβ β-amyloid status by Pittsburgh compound B PET scan or CSF Aβ₄₂ < 250 pg/ml
Median (min, max)
^┼Missing data
*NC higher than bvFTD, nfvPPA, MAPT, C9ORF72 and PGRN and carriers p < 0.05
**nfvPPA lower than bvFTD and MAPT carriers p < 0.05
^‡Aβ status not available in 9 subjects due to age < 60

ISSN: 1758-9193